Results 171 to 180 of about 8,165 (189)

Cardiovascular safety of febuxostat – Authors' reply

Lancet, The, 2021
Isla S Mackenzie
exaly  

Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial

Lancet, The, 2020
Isla S Mackenzie, Stuart H Ralston, Raffaele De Caterina   +2 more
exaly  

Febuxostat

Reactions Weekly, 2022
  +4 more sources

Febuxostat

Reactions Weekly, 2021
openaire   +1 more source

FAST: new look at the febuxostat safety profile

Lancet, The, 2020
Thomas Bardin, Pascal Richette
exaly  

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

New England Journal of Medicine, 2018
William B White, Kenneth G Saag, Philip B Gorelick   +2 more
exaly  

Formulation, optimization and in vitro–in vivo evaluation of febuxostat nanosuspension

International Journal of Pharmaceutics, 2015
Sarasija Suresh
exaly  

Cardiovascular Safety of Febuxostat

New England Journal of Medicine, 2018
William B White
exaly  

Febuxostat for Cerebral and CaRdiorenovascular Events PrEvEntion StuDy

European Heart Journal, 2019
Sunao Kojima, Kunihiko Matsui, Yusuke Ohya   +2 more
exaly  

Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice

International Immunopharmacology, 2019
Keyvan Amirshahrokhi
exaly